Eisai And Solvay Submit NDA For Creon In Japan
This article was originally published in PharmAsia News
Executive Summary
Eisia And Japanese Solvay Pharmaceuticals subsidiary Solvay Seiyaku submitted an NDA for SA-001 (pancrelipase) for pancreatic exocrine insufficiency in Japan